Résultats de la recherche - Xiaohui Zeng

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer par Xia Luo, Zhen Zhou, Xiaohui Zeng, Qiao Liu

Connect to this object online.

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China par Liu Qiao, Zhen Zhou, Xiaohui Zeng, Chongqing Tan

Connect to this object online.

Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectiveness par Xiaohui Zeng, Zhen Zhou, Xia Luo, Qiao Liu

Connect to this object online.

Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients Wit... par Haixia Zhang, Xiaohui Zeng, Ye Peng, Chongqing Tan, Xiaomin Wan

Connect to this object online.

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in Chi... par Xia Luo, Zhen Zhou, Xiaohui Zeng, Liubao Peng, Qiao Liu

Connect to this object online.

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis par Xiaohui Zeng, Qiao Liu, Chongqing Tan, Xiaomin Wan, Yunhua Wang, Xiaowei Ma

Connect to this object online.

Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis par Chongqing Tan, Xia Luo, Zhen Zhou, Xiaohui Zeng, Xiaomin Wan, Lidan Yi, Qiao Liu

Connect to this object online.

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China par Dongchu Zhou, Xia Luo, Zhen Zhou, Xiaohui Zeng, Xiaomin Wan, Chongqing Tan, Qiao Liu

Connect to this object online.

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis par Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng

Connect to this object online.

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50% par Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng

Connect to this object online.

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell L... par Xia Luo, Qiao Liu, Zhen Zhou, Lidan Yi, Liubao Peng, Xiaomin Wan, Xiaohui Zeng, Chongqing Tan, Sini Li

Connect to this object online.

Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study par Shuxia Qin, Xuehong Wang, Sini Li, Sini Li, Chongqing Tan, Xiaohui Zeng, Meiyu Wu, Ye Peng, Liting Wang, Xiaomin Wan

Connect to this object online.

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer par Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Qijian Deng, Chongqing Tan

Connect to this object online.

Selection and evaluation of quality control markers in propolis based on its hyperlipidemia therapy via regulating PXR/CYP3A4 expression par Zhao Chen, Wenhui Luo, Dongmei Sun, Xiaoli Bi, Xiaohui Zeng, Guanlin Xiao, Aili Xu, Weitao Chen, Jieyi Jiang, Xiyuan Li, Lizhong Cao

Connect to this object online.

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis par Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan, Chongqing Tan

Connect to this object online.

The anti-hyperlipidemia effect of Yinlan capsule via regulation of PXR activity par Zhao Chen, Dongmei Li, Xi-Yuan Li, Guanlin Xiao, Xiaoli Bi, Weitao Chen, Zhiqi Shi, Xiaohui Zeng, Dongmei Sun, Li-Zhong Cao

Connect to this object online.

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer par Meiyu Wu, Meiyu Wu, Shuxia Qin, Shuxia Qin, Liting Wang, Liting Wang, Chongqing Tan, Chongqing Tan, Ye Peng, Ye Peng, Xiaohui Zeng, Xia Luo, Xia Luo, Lidan Yi, Lidan Yi, Xiaomin Wan, Xiaomin Wan

Connect to this object online.

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review par Meiyu Wu, Meiyu Wu, Shuxia Qin, Shuxia Qin, Liting Wang, Liting Wang, Chongqing Tan, Chongqing Tan, Ye Peng, Ye Peng, Xiaohui Zeng, Xia Luo, Xia Luo, Lidan Yi, Lidan Yi, Xiaomin Wan, Xiaomin Wan

Connect to this object online.